omadacycline
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Omadacycline (Paratek Pharmaceuticals) is the first agent of the aminomethycyclines class of antibiotics. The drug, which is a semisynthetic derivative of the tetracycline minocycline, exerts its antibacterial effect by binding to the tetracycline binding sites on bacterial ribosomes, leading to the inhibition of bacterial protein synthesis. Omadacycline has an antibacterial spectrum that covers a range of Gram-positive and Gram-negative bacterial pathogens. It has demonstrated potent in vitro activity against a number of significant respiratory pathogens such as Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis. The drug was also active against bacterial strains with tetracycline and penicillin resistance.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 omadacycline : Community-acquired pneumonia
LIST OF FIGURES
6 Figure 1: Omadacycline – development overview
7 Figure 2: Omadacycline for community-acquired pneumonia – SWOT analysis
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of omadacycline in community-
acquired pneumonia
9 Figure 4: Datamonitor Healthcare’s drug assessment summary of omadacycline in community-
acquired pneumonia
LIST OF TABLES
4 Table 1: Omadacycline drug profile
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Accountable Care Organizations – What Impact on Pharma 
Sign up to the